Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus gemcitabine versus gemcitabine in refractory or later-line advanced epithelial ovarian cancer
2013-000491-14Phase 2Active
- Sponsor
- AB Science
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in epithelial ovarian cancer (EOC) comparing Masitinib + gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started Feb 2014; status: active.
02
Drugs
masitinibgemcitabine
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2013-000491-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000491-14.